Jessica Freydman, PharmD

In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.

A clinical pharmacy manager and a pharmacy resident detail the unique mechanism of action of tepotinib for metastatic non–small cell lung cancer with mutations in MET exon 14.